Bard’s Flair stent graft
This article was originally published in The Gray Sheet
Executive Summary
C.R. Bard receives PMA approval for endovascular stent graft with optimized delivery system to treat stenoses in synthetic arteriovenous byplass grafts Oct. 29, following a six-month, prospective, randomized pivotal study of 190 patients at 16 sites. The study showed that Flair resulted in more than twice the primary patency of balloon angioplasty, the firm said